Portfolio

Prilenia Therapeutics

CEO Michael R. Hayden

Prilenia is a clinical stage biotech company

Prilenia is a clinical stage biotech startup founded in 2018 with the purpose of improving the lives of patients and their families by developing treatments for neurodegenerative and neurodevelopmental disorders focused on the registration of pridopidine in Huntington’s Disease and ALS in 2 pivotal clinical trials.

Prilenia is based in Naarden, the Netherlands, Herzliya, Israel and Boston, MA in the U.S.

Human Health

Prilenia logo

Industry

Biotech

Status

Current

Location

Israel